{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:34:54Z","timestamp":1791261294246,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N34E690030"],"award-info":[{"award-number":["N34E690030"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","award":["R016737004"],"award-info":[{"award-number":["R016737004"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["R016110006"],"award-info":[{"award-number":["R016110006"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["R016210017"],"award-info":[{"award-number":["R016210017"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["N42A650364"],"award-info":[{"award-number":["N42A650364"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011852","name":"Paracelsus Medizinische Privatuniversit\u00e4t","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021186","name":"Office of National Higher Education Science Research and Innovation Policy Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119897","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:13:28Z","timestamp":1788268408000},"page":"119897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Triple-costimulatory GD2-CAR T cells incorporating CD28, 4\u20131BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-8031","authenticated-orcid":false,"given":"Jatuporn","family":"Sujjitjoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katesara","family":"Kongkla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornpimon","family":"Yuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-9948","authenticated-orcid":false,"given":"Nunghathai","family":"Sawasdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krissada","family":"Natungnuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naravat","family":"Poungvarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5927","authenticated-orcid":false,"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.biopha.2026.119897_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119897_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.biopha.2026.119897_bib3","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119897_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.biopha.2026.119897_bib5","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.biopha.2026.119897_bib6","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2026.119897_bib7","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors: A review of the intricate mechanisms and potential strategies","volume":"168","author":"Arora","year":"2026","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119897_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119897_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1433518","article-title":"Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma","volume":"7","author":"Quintarelli","year":"2018","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.biopha.2026.119897_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"issue":"12 Pt 1","key":"10.1016\/j.biopha.2026.119897_bib12","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2026.119897_bib13","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1083\/jcb.102.5.1887","article-title":"Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin","volume":"102","author":"Cheresh","year":"1986","journal-title":"J. Cell. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0014-5793(86)81522-8","article-title":"GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression","volume":"208","author":"Thurin","year":"1986","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.biopha.2026.119897_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ijc.2910410303","article-title":"Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma","volume":"41","author":"Hersey","year":"1988","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00310922","article-title":"Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas","volume":"82","author":"Longee","year":"1991","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13569-014-0020-9","article-title":"Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma","volume":"5","author":"Poon","year":"2015","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.biopha.2026.119897_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yexmp.2019.05.001","article-title":"High GD2 expression defines breast cancer cells with enhanced invasiveness","volume":"109","author":"Mansoori","year":"2019","journal-title":"Exp. Mol. Pathol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119897_bib19","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ijc.2910530614","article-title":"Shedding of GD2 ganglioside in patients with retinoblastoma","volume":"53","author":"Portoukalian","year":"1993","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib20","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41598-025-34331-6","article-title":"B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma","volume":"16","author":"Sujjitjoon","year":"2026","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119897_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100971","article-title":"GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction","volume":"14","author":"Sujjitjoon","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2026.119897_bib22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119897_bib23","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cas.70011","article-title":"GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics","volume":"116","author":"Furukawa","year":"2025","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119897_bib24","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3389\/fimmu.2018.02380","article-title":"CAR T Cell Therapy for Neuroblastoma","author":"Richards","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell. Rep."},{"issue":"14","key":"10.1016\/j.biopha.2026.119897_bib26","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119897_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1082771","article-title":"Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma","volume":"13","author":"Wieczorek","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119897_bib28","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.1097\/MPH.0000000000002488","article-title":"First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma","volume":"44","author":"Spasov","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119897_bib29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejca.2022.05.035","article-title":"Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group","volume":"172","author":"Hingorani","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119897_bib30","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119897_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200914","article-title":"ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype","volume":"13","author":"Moreno-Cortes","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119897_bib32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4161\/onci.19458","article-title":"Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy","volume":"1","author":"Song","year":"2012","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","article-title":"Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial","volume":"16","author":"Schubert","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119897_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119897_bib35","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.20030916","article-title":"CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool","volume":"198","author":"Hendriks","year":"2003","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119897_bib36","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.4049\/jimmunol.1000159","article-title":"The Pim kinase pathway contributes to survival signaling in primed CD8+ T cells upon CD27 costimulation","volume":"185","author":"Peperzak","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-020-06032-3","article-title":"Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy","volume":"186","author":"Luangwattananun","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2026.119897_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric Antigen Receptor T Cells Targeting Integrin alphavbeta6 Expressed on Cholangiocarcinoma Cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib39","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119897_bib40","article-title":"Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains","volume":"11","author":"Wutti-In","year":"2021","journal-title":"Front. Oncol."},{"issue":"Pt B","key":"10.1016\/j.biopha.2026.119897_bib41","article-title":"Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition","volume":"113","author":"Yuti","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.biopha.2026.119897_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119897_bib44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell."},{"key":"10.1016\/j.biopha.2026.119897_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2026.119897_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12032-023-01959-1","article-title":"CD27 agonism coordinates with CD28 and 4-1BB signal to augment the efficacy of CAR-T cells in colorectal tumor","volume":"40","author":"Zhang","year":"2023","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119897_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/imm.70019","article-title":"GD2-CAR T Cell Therapy for H3K27M (+) Diffuse Intrinsic Pontine Glioma: A Phase I Clinical Trial and Mechanistic Insights","volume":"177","author":"Jiang","year":"2026","journal-title":"Immunology"},{"issue":"7903","key":"10.1016\/j.biopha.2026.119897_bib48","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","article-title":"Anti-GD2\/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients","volume":"11","author":"Yu","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119897_bib50","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","volume":"148","author":"Yu","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119897_bib51","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/2767-9764.CRC-23-0259","article-title":"Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer","volume":"4","author":"Kinoshita","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119897_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1683345","article-title":"GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells","volume":"9","author":"Seitz","year":"2020","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.biopha.2026.119897_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.102014","article-title":"Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma","volume":"28","author":"Natungnuy","year":"2026","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.biopha.2026.119897_bib54","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:58:47Z","timestamp":1790081927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"alternative-id":["S0753332226009339"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119897","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple-costimulatory GD2-CAR T cells incorporating CD28, 4\u20131BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119897"}}